STOCKHOLM, Sweden, June 22, 2026
BioArctic AB and Eli Lilly and Company have entered into a major research and collaboration agreement aimed at developing a potential next-generation treatment for neurodegenerative diseases by combining BioArctic’s proprietary BrainTransporter™ technology with an undisclosed Lilly drug candidate. The collaboration represents another significant milestone in the rapidly evolving field of neurological drug development, where overcoming the blood-brain barrier remains one of the industry’s greatest scientific challenges. Under the agreement, BioArctic will receive an upfront payment of USD 30 million and may earn up to USD 770 million in additional milestone payments, along with tiered mid-single-digit royalties on future global sales if the therapy reaches commercialization. The partnership highlights growing pharmaceutical industry interest in advanced drug delivery platforms capable of improving treatment effectiveness for devastating neurological disorders such as Alzheimer’s disease, Parkinson’s disease, ALS, and other neurodegenerative conditions.
BrainTransporter Technology Aims to Improve Drug Delivery to the Brain
A central focus of the collaboration is BioArctic’s proprietary BrainTransporter™ platform, a technology specifically designed to enhance the transport of therapeutic molecules across the blood-brain barrier through the transferrin receptor pathway. The blood-brain barrier has historically limited the effectiveness of many biologic therapies by restricting access to disease targets within the central nervous system. By enabling active transport into brain tissue, BrainTransporter technology has the potential to improve drug distribution, increase therapeutic efficacy, enhance safety profiles, and simplify dosing strategies.
Under the agreement, BioArctic will generate a novel drug candidate that integrates the BrainTransporter platform with Lilly’s proprietary molecule, creating a new therapeutic approach for neurodegenerative disorders. Once the candidate is identified, Lilly will assume full responsibility for global development, regulatory activities, manufacturing, and commercialization, leveraging its extensive neuroscience expertise and worldwide commercial infrastructure to advance the program toward patients.
Strategic Partnership Expands Neurodegenerative Disease Innovation
Advertisement
The agreement marks the fourth major collaboration involving BioArctic’s BrainTransporter technology, further validating the platform’s scientific and commercial potential. Previous partnerships involving the technology include agreements with Eisai, Bristol Myers Squibb, and Novartis, demonstrating strong pharmaceutical industry confidence in BioArctic’s approach to brain-targeted therapeutics. Importantly, BioArctic retains rights to utilize the BrainTransporter platform outside the scope of existing agreements, preserving opportunities for future collaborations across multiple disease areas.
Chief Executive Officer Gunilla Osswald emphasized that the partnership reflects recognition from one of the world’s leading pharmaceutical companies regarding the transformative potential of BrainTransporter technology. She noted that both organizations share a commitment to developing innovative solutions for patients suffering from severe neurological diseases, where treatment options remain limited despite growing global disease prevalence.
Strengthening the Future of Neurodegenerative Drug Development
The collaboration further strengthens BioArctic’s position as a leading innovator in neurodegenerative disease research. The company is internationally recognized for inventing Leqembi® (lecanemab), the first therapy shown to slow disease progression and reduce cognitive decline in early Alzheimer’s disease. Building on that success, BioArctic continues to advance a broad pipeline targeting Alzheimer’s disease, Parkinson’s disease, ALS, and other neurological disorders. The partnership with Lilly underscores a broader industry trend toward combining innovative therapeutic molecules with advanced delivery technologies to improve clinical outcomes.
As pharmaceutical companies increasingly seek solutions capable of overcoming biological barriers in the brain, collaborations such as this one are expected to play a critical role in accelerating the development of next-generation neuroscience therapies. With potential payments exceeding USD 800 million and the possibility of future royalties, the agreement represents a significant commercial opportunity while advancing the shared goal of delivering transformative treatments to patients worldwide affected by debilitating neurodegenerative diseases.
Source: BioArctic, Eli Lilly press release
